HCG.BO(HCG.BO)
HCG.BO
$693.65—Stale · unknown old
BSE • Last print unknown ago
$693.65—Stale · unknown old
No analyst ratings available
No analyst price targets available for HCG.BO
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2027E | FY2028E | FY2029E |
|---|---|---|---|
| Revenue Avg | $29.06B | $33.23B | $38.51B |
| Low | $28.28B | $32.01B | $36.84B |
| High | $30.11B | $34.49B | $40.47B |
| EBITDA Avg | $6.03B | $7.54B | $9.29B |
| Low | $5.09B | $5.95B | $9.11B |
| High | $6.31B | $7.86B | $9.46B |
| EBIT Avg | $3.57B | $5.00B | $6.58B |
| Low | $2.63B | $3.40B | $6.40B |
| High | $3.85B | $5.31B | $6.76B |
| Net Income Avg | $1.37B | $2.31B | $3.34B |
| Low | $759M | $1.26B | $3.23B |
| High | $1.56B | $2.51B | $3.46B |
| EPS Avg | $8.92 | $15.24 | $23.06 |
| Low | $5.29 | $8.81 | $22.51 |
| High | $10.87 | $17.52 | $24.12 |
| Analysts (Rev / EPS) | 11 / 8 | 11 / 9 | 4 / 3 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 |
|---|---|---|---|---|
| Revenue Avg | $7.34B | $7.33B | $7.46B | $8.04B |
| Low | $7.30B | $7.22B | $7.39B | $7.96B |
| High | $7.37B | $7.45B | $7.54B | $8.13B |
| EBITDA Avg | $1.58B | $1.56B | $1.82B | $1.99B |
| Low | $1.57B | $1.55B | $1.81B | $1.98B |
| High | $1.58B | $1.57B | $1.83B | $2.00B |
| EBIT Avg | $876M | $862M | $1.12B | $1.30B |
| Low | $870M | $856M | $1.11B | $1.29B |
| High | $882M | $868M | $1.13B | $1.31B |
| Net Income Avg | $295M | $286M | $457M | $570M |
| Low | $291M | $282M | $450M | $563M |
| High | $299M | $290M | $463M | $578M |
| EPS Avg | $1.97 | $1.91 | $3.05 | $3.81 |
| Low | $1.94 | $1.88 | $3.01 | $3.76 |
| High | $2.00 | $1.94 | $3.09 | $3.86 |
| Analysts (Rev / EPS) | 2 / 1 | 2 / 1 | 1 / 1 | 1 / 1 |